Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
GLP1 Receptor Agonists are very valuable drugs, both to consumers who want help with weight management or type 2 diabetes, and companies that are looking for profitable drug candidates. Despite this, not every GLP1 formulation makes it to market.
Check out our quick explainer
While intense competition can breed higher quality drugs, it can cause overlooking of deficiencies in existing formulations in a rush to get to market. Thanks to vigilance on the part of (and likely some competitive pressures), Danuglipron is not one of those cases.
The end of Danuglipron as a possible future GLP1 that increases accessibility and drives down prices is regrettable, but the continuation of GLP1 as an incredibly safe and well-researched choice for weight management and treatment of type 2 diabetes is worth celebrating.
Why is development stopping in Danuglipron?
Development is stopping because of a case of drug induced injury
a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron.
Thankfully, development of Danuglipron is ending promptly, and thus reducing the possibility of drug-induced liver failures in the future.
It's not clear what will happen to the IP related to Danuglipron – some may find the side-effects (and likelihood of them occurring) might be acceptable risks, but at present Pfizer (at least) does not consider it prudent to keep developing the drug.
What are other GLP1s under active development?
Thankfully, there are many other GLP1s under active development:
GLP1.Guide Staff
GLP1.Guide Staff
GLP1.Guide Staff
GLP1.Guide Staff
This isn't a complete list but we strive to keep up to date with the development of alternative GLP1 fomulations.
